The estimated Net Worth of Holding, S.A. Biodyne is at least $15.9 million dollars as of 11 June 2020. Holding Biodyne owns over 1,950,000 units of Hancock Jaffe Laboratories Inc stock worth over $14,588,395 and over the last 5 years Holding sold HJLI stock worth over $1,313,267.
Sign up
Holding Biodyne HJLI stock SEC Form 4 insiders trading
Holding has made over 3 trades of the Hancock Jaffe Laboratories Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Holding sold 1,950,000 units of HJLI stock worth $780,000 on 11 June 2020.
The largest trade Holding's ever made was selling 1,950,000 units of Hancock Jaffe Laboratories Inc stock on 11 June 2020 worth over $780,000. On average, Holding trades about 715,099 units every 93 days since 2019. As of 11 June 2020 Holding still owns at least 1,405,433 units of Hancock Jaffe Laboratories Inc stock.
You can see the complete history of Holding Biodyne stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Holding Biodyne's mailing address?
Holding's mailing address filed with the SEC is 13 RUE DE LA GARE, , MORGES, V8, 1110.
Insiders trading at Hancock Jaffe Laboratories Inc
Over the last 6 years, insiders at Hancock Jaffe Laboratories Inc have traded over $1,313,267 worth of Hancock Jaffe Laboratories Inc stock and bought 39,132 units worth $123,953 . The most active insiders traders include Holding, S.A. Biodyne, Robert Andrew Berman et Francis Duhay. On average, Hancock Jaffe Laboratories Inc executives and independent directors trade stock every 100 days with the average trade being worth of $3,344,125. The most recent stock trade was executed by Matthew Jenusaitis on 25 August 2021, trading 1,300 units of HJLI stock currently worth $10,010.
What does Hancock Jaffe Laboratories Inc do?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
What does Hancock Jaffe Laboratories Inc's logo look like?
Complete history of Holding Biodyne stock trades at Hancock Jaffe Laboratories Inc
Hancock Jaffe Laboratories Inc executives and stock owners
Hancock Jaffe Laboratories Inc executives and other stock owners filed with the SEC include:
-
Robert A. Berman,
CEO & Director -
Dr. Marc H. Glickman,
Sr. VP & Chief Medical Officer -
Craig Thomas Glynn,
CFO & Treasurer -
Dr. Benedict Broennimann M.D.,
Chief Medical Officer of Outside of United States -
Warren Hancock,
Co-founder -
Marc H. Glickman,
SVP & Chief Medical Officer -
Marcus W. Robins,
Director -
Sanjay Shrivastava,
Director -
Benedict Broennimann,
Chief Medical Officer, OUS -
Francis Duhay,
Director -
Holding, S.A. Biodyne,
-
Robert Gray,
Director -
Matthew Jenusaitis,
Director -
Craig Glynn,
Chief Financial Officer